 |
| (file photo) |
SHIJIAZHUANG, March 17 (Xinhua) -- A major Chinese drug maker has said it will appeal massive antitrust fines ordered by a U.S. federal court in New York.
The Brooklyn Federal Court ruled Thursday that the North China Pharmaceutical Group Corp. (NCPC) and its affiliate Hebei Welcome Pharmaceutical Co., Ltd. must pay 162 million U.S. dollars in fines after finding that they colluded in order to raise prices for vitamin C exports to the U.S. market.
The ruling marked the first time for a Chinese pharmaceutical company to be fined in a U.S. antitrust case.
The NCPC said late Saturday that it would appeal the fines after receiving the official verdict from the U.S. federal court.
The company, one of China's four-largest vitamin and antibiotic suppliers, added that it will also disclose information regarding the case's progress in a timely way.
Shares of North China Pharmaceutical Co. Ltd. were suspended from Friday afternoon trading in Shanghai in response to the ruling.
The ruling was the result of a lawsuit lodged by two U.S. companies in which they accused Chinese vitamin C exporters of working together to raise prices for years, raising vitamin C prices in the U.S. from 2.5 U.S. dollars per kg to 15 dollars per kg.
Another two Chinese vitamin C exporters named in the case settled the lawsuit out of court.
Xie Yongfa, an official with the Hebei provincial department of commerce, said trade protectionism in the U.S. has been rising in recent years, with more anti-dumping cases lodged against Chinese goods.
Xie said he hopes both sides can work together to maintain a free, open and fair international trade environment, as well as deal with trade frictions in a rational way.
"The case also teaches Chinese firms a lesson: they should try to avoid violating anti-trust laws, as any related punishment could be deadly," he said.
Beijing's 2013 pollution goals set far too low: experts
Feedback
RSS
